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Abstract
The European Committee on Antimicrobial Susceptibility Test-
ing-Subcommittee on Antifungal Susceptibility Testing has deter-
mined breakpoints for anidulafungin for Candida spp. This
Technical Note is based on the EUCAST anidulafungin rationale
document (available at: http://www.eucast.org). Species-speciﬁc
breakpoints for C. albicans are S £0.03 mg/L and R >0.03 mg/L
and for C. glabrata, C. tropicalis and C. krusei S £0.06 mg/L and R
>0.06 mg/L. C. parapsilosis was not regarded a good target for
anidulafungin. There are insufﬁcient data to set breakpoints for
other species. The breakpoints are based upon pharmacokinetic
data, epidemiological cut-off values and clinical experience.
Breakpoints will be reviewed regularly.
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Anidulafungin is an echinocandin antifungal agent active
against most Candida species. Anidulafungin is predominantly
used for the treatment of disseminated candidiasis in non-
neutropenic adult patients. Most data regarding anidulafungin
in vitro susceptibility are derived from patients with candida-
emia and a smaller number of patients with deep-seated
organ infection.
The European Committee on Antimicrobial Susceptibility
Testing-Subcommittee on Antifungal Susceptibility Testing
(EUCAST-AFST) has determined breakpoints for anidulafun-
gin for Candida spp. This Technical Note is based on the
EUCAST anidulafungin rationale document (available on the
EUCAST website: http://www.eucast.org). The rationale doc-
ument includes more detail and published references related
to the selection of EUCAST-AFST breakpoints (http://
www.srga.org/eucastwt/MICTAB/EUCAST%20clinical%20MIC
%20breakpoints%20-%20antimicrobials%20for%20Candida%20
infections.htm).
The breakpoints are based on dosages of 200 mg/kg on
day 1, then 100 mg/kg/day, and were established using
MIC values from many sources. Wild-type isolates exhibit
MICs of C. albicans £0.03 mg/L, C. glabrata, C. krusei and
C. tropicalis £0.06 mg/L and C. parapsilosis £4 mg/L. Isolates
with mutations in the hot spot regions of the target gene
have been associated with clinical failures or breakthrough
infections during echinocandin treatment [1–3]. The anidu-
lafungin MICs of such mutant isolates are as follows:
C. albicans >0.03 mg/L, C. glabrata >0.06 mg/L, C. tropicalis
>0.06 mg/L and C. krusei >0.03 mg/L [4]. However, it
should be noted that most of the data on breakthrough
infections derive from studies with caspofungin as caspo-
fungin has been in use the longest (approved in Europe in
2001, whereas anidulafungin was approved in 2007). The
clinical data from three clinical trials were used [5–7].
These studies did not include MICs by the EUCAST
method so a correlation of in vitro MICs with clinical
outcome is not possible.
The EUCAST breakpoints (Table 1) are based on pharma-
cokinetic and microbiological data and clinical experience
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[4–9]. Breakpoints for anidulafungin will be reviewed regu-
larly. A number of in vitro studies on susceptibility of the fun-
gus, of the target enzyme itself or in animal models have
demonstrated cross-resistance between the three currently
available echinocandins (anidulafungin, caspofungin and mica-
fungin) for isolates with hot spot mutations in the target
gene [3,10–15]. Hence, isolates categorized as anidulafungin
susceptible can be regarded as susceptible to caspofungin
and micafungin until drug-speciﬁc breakpoints are available
for these two compounds.
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